TY - JOUR
T1 - Antibody responses to SARS-CoV-2
T2 - Let’s stick to known knowns
AU - Baumgarth, Nicole
AU - Nikolich-Žugich, Janko
AU - Lee, F. Eun Hyung
AU - Bhattacharya, Deepta
N1 - Funding Information:
This work was supported by Office of Extramural Research, National Institutes of Health Grants R01AI099108 (to D.B.), R01AI121252 (to F.E.-H.L.), R01AI117890 (to N.B.), R01AI148652 (to N.B.), and R37AG020719 (to J.N.-Zˇ.).
Funding Information:
D.B. has intellectual property licensed by Sana Biotechnology. F.E.-H.L. is a founder of MicroB-plex, Inc., and receives research funding from Genentech. J.N.-Zˇ . is on the scientific advisory board of and receives research funding from Young Blood, Inc. The other author has no financial conflicts of interest.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - The scale of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has thrust immunology into the public spotlight in unprecedented ways. In this article, which is part opinion piece and part review, we argue that the normal cadence by which we discuss science with our colleagues failed to properly convey likelihoods of the immune response to SARS-CoV-2 to the public and the media. As a result, biologically implausible outcomes were given equal weight as the principles set by decades of viral immunology. Unsurprisingly, questionable results and alarmist news media articles have filled the void. We suggest an emphasis on setting expectations based on prior findings while avoiding the overused approach of assuming nothing. After reviewing Ab-mediated immunity after coronavirus and other acute viral infections, we posit that, with few exceptions, the development of protective humoral immunity of more than a year is the norm. Immunity to SARS-CoV-2 is likely to follow the same pattern.
AB - The scale of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has thrust immunology into the public spotlight in unprecedented ways. In this article, which is part opinion piece and part review, we argue that the normal cadence by which we discuss science with our colleagues failed to properly convey likelihoods of the immune response to SARS-CoV-2 to the public and the media. As a result, biologically implausible outcomes were given equal weight as the principles set by decades of viral immunology. Unsurprisingly, questionable results and alarmist news media articles have filled the void. We suggest an emphasis on setting expectations based on prior findings while avoiding the overused approach of assuming nothing. After reviewing Ab-mediated immunity after coronavirus and other acute viral infections, we posit that, with few exceptions, the development of protective humoral immunity of more than a year is the norm. Immunity to SARS-CoV-2 is likely to follow the same pattern.
UR - http://www.scopus.com/inward/record.url?scp=85093497960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093497960&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2000839
DO - 10.4049/jimmunol.2000839
M3 - Review article
C2 - 32887754
AN - SCOPUS:85093497960
VL - 205
SP - 2342
EP - 2350
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 9
ER -